Engaging the Canadian public on reimbursement decision-making for drugs for rare diseases: a national online survey
Abstract Background Funding of drugs for rare diseases (DRDs) requires decisions that balance fairness for all individuals within the healthcare system with compassion for affected individuals. Our study objective was to conduct a national online survey to determine the Canadian public’s perspective...
Main Authors: | Julie Polisena, Michael Burgess, Craig Mitton, Larry D. Lynd |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-05-01
|
Series: | BMC Health Services Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12913-017-2310-4 |
Similar Items
-
What is the role of antineoplastic drug safety in reimbursement decision making?
by: A. S. Kolbin, et al.
Published: (2018-11-01) -
Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries
by: Szczepan Jakubowski, et al.
Published: (2024-03-01) -
Criteria for Drug Reimbursement Decision-Making: An Emerging Public Health Challenge in Bulgaria
by: Georgi Iskrov, et al.
Published: (2016-02-01) -
Drug pricing and reimbursement decision making systems in Mongolia
by: Gereltuya Dorj, et al.
Published: (2017-12-01) -
Reimbursement decision-making system in Poland systematically compared to other countries
by: Aneta Mela, et al.
Published: (2023-10-01)